Galmed Announces First Time Results In Prostate Oncology Studies Aramchol Demonstrates 3-4 Fold Increase In Cell Death Compared To Enzalutamide Alone In Prostate Cancer Models
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced first-time results in prostate oncology studies: Aramchol demonstrates a 3-4 fold increase in cell death compared to enzalutamide (Xtandi®) alone in prostate cancer models.
Galmed Announces First Time Results In Prostate Oncology Studies Aramchol Demonstrates 3-4 Fold Increase In Cell Death Compared To Enzalutamide Alone In Prostate Cancer Models - GLMD News | Rallies
GLMD•
